Telomir Pharmaceuticals (TELO) Competitors $1.42 +0.02 (+1.43%) Closing price 04:00 PM EasternExtended Trading$1.96 +0.55 (+38.38%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TELO vs. TRDA, VOR, BDTX, MDWD, DERM, CCCC, CHRS, FBRX, BIOA, and SLSShould you be buying Telomir Pharmaceuticals stock or one of its competitors? The main competitors of Telomir Pharmaceuticals include Entrada Therapeutics (TRDA), Vor Biopharma (VOR), Black Diamond Therapeutics (BDTX), MediWound (MDWD), Journey Medical (DERM), C4 Therapeutics (CCCC), Coherus Oncology (CHRS), Forte Biosciences (FBRX), BioAge Labs (BIOA), and SELLAS Life Sciences Group (SLS). These companies are all part of the "pharmaceutical products" industry. Telomir Pharmaceuticals vs. Its Competitors Entrada Therapeutics Vor Biopharma Black Diamond Therapeutics MediWound Journey Medical C4 Therapeutics Coherus Oncology Forte Biosciences BioAge Labs SELLAS Life Sciences Group Entrada Therapeutics (NASDAQ:TRDA) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation. Does the media refer more to TRDA or TELO? In the previous week, Entrada Therapeutics and Entrada Therapeutics both had 1 articles in the media. Entrada Therapeutics' average media sentiment score of 1.34 beat Telomir Pharmaceuticals' score of 1.00 indicating that Entrada Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Entrada Therapeutics Positive Telomir Pharmaceuticals Positive Do insiders & institutionals believe in TRDA or TELO? 86.4% of Entrada Therapeutics shares are owned by institutional investors. 7.6% of Entrada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is TRDA or TELO more profitable? Telomir Pharmaceuticals has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -92.30%. Entrada Therapeutics' return on equity of -17.81% beat Telomir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Entrada Therapeutics-92.30% -17.81% -14.55% Telomir Pharmaceuticals N/A -4,595.08%-1,750.91% Which has stronger valuation & earnings, TRDA or TELO? Entrada Therapeutics has higher revenue and earnings than Telomir Pharmaceuticals. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntrada Therapeutics$210.78M1.07$65.63M-$1.78-3.33Telomir PharmaceuticalsN/AN/A-$16.53M-$0.54-2.63 Do analysts prefer TRDA or TELO? Entrada Therapeutics presently has a consensus target price of $25.67, indicating a potential upside of 333.56%. Telomir Pharmaceuticals has a consensus target price of $15.00, indicating a potential upside of 956.34%. Given Telomir Pharmaceuticals' higher possible upside, analysts plainly believe Telomir Pharmaceuticals is more favorable than Entrada Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entrada Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67Telomir Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Which has more risk & volatility, TRDA or TELO? Entrada Therapeutics has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500. Comparatively, Telomir Pharmaceuticals has a beta of -0.6, meaning that its stock price is 160% less volatile than the S&P 500. SummaryEntrada Therapeutics beats Telomir Pharmaceuticals on 9 of the 13 factors compared between the two stocks. Get Telomir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TELO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TELO vs. The Competition Export to ExcelMetricTelomir PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.19M$2.62B$6.16B$10.57BDividend YieldN/A56.38%5.66%4.69%P/E Ratio-2.6324.4085.5827.12Price / SalesN/A744.84612.62135.31Price / CashN/A28.3526.3031.10Price / Book71.005.3712.876.67Net Income-$16.53M$32.78M$3.30B$276.23M7 Day Performance5.97%3.90%4.80%3.31%1 Month Performance14.52%9.99%8.11%10.76%1 Year Performance-73.85%-3.12%75.85%33.58% Telomir Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TELOTelomir Pharmaceuticals3.1101 of 5 stars$1.42+1.4%$15.00+956.3%-74.2%$45.19MN/A-2.631Positive NewsShort Interest ↓High Trading VolumeTRDAEntrada Therapeutics3.1621 of 5 stars$5.09-3.6%$25.67+404.3%-64.9%$200.84M$79.48M-2.86110Positive NewsVORVor BiopharmaN/A$31.28+12.0%$121.33+287.9%N/A$198.13MN/A-18.96140Gap DownBDTXBlack Diamond Therapeutics3.5392 of 5 stars$3.17-7.3%$11.67+268.0%+3.7%$194.72MN/A13.7890Positive NewsMDWDMediWound1.5387 of 5 stars$17.86-0.5%$32.25+80.6%+2.8%$194.00M$19.86M-6.7780DERMJourney Medical1.4811 of 5 stars$7.51+2.9%$12.17+62.0%+12.3%$192.06M$56.13M-19.7690CCCCC4 Therapeutics3.7082 of 5 stars$2.59-0.8%$8.50+228.2%-57.8%$185.76M$35.58M-1.64150Gap UpHigh Trading VolumeCHRSCoherus Oncology4.2957 of 5 stars$1.56-1.9%$4.51+189.3%+57.7%$184.80M$272.21M1.01330FBRXForte Biosciences3.1099 of 5 stars$15.86+7.3%$68.00+328.8%+208.6%$183.82MN/A-0.975BIOABioAge Labs0.2749 of 5 stars$4.94-3.3%N/AN/A$183.19MN/A0.00N/ASLSSELLAS Life Sciences Group2.0827 of 5 stars$1.70-1.2%$7.00+311.8%+48.4%$181.11M$1M-5.3110Positive NewsShort Interest ↓ Related Companies and Tools Related Companies Entrada Therapeutics Alternatives Vor Biopharma Alternatives Black Diamond Therapeutics Alternatives MediWound Alternatives Journey Medical Alternatives C4 Therapeutics Alternatives Coherus Oncology Alternatives Forte Biosciences Alternatives BioAge Labs Alternatives SELLAS Life Sciences Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TELO) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredIs This Warren’s Buffett’s #1 AI Investment?Did you know that Warren Buffett is investing in what Jeff Brown believes will be the next generation of artif...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
